US regulators to weigh controversial peptides backed by RFK Jr | Health News
FDA to Review Safety of Popular Peptides Amid Rising Demand
Published: July 22, 2026
The U.S. Food and Drug Administration (FDA) is set to evaluate the safety and efficacy of several peptides, compounds increasingly touted as wellness treatments. Originally popular in niche bodybuilding and biohacking communities, peptides are now being marketed for a wide array of uses, including weight loss, muscle growth, and anti-aging.
The Pharmacy Compounding Advisory Committee will convene on Thursday and Friday to assess whether seven specific peptides can be manufactured by licensed compounding pharmacies for prescription use. The FDA’s growing scrutiny comes as evidence regarding the safety and effectiveness of these compounds remains unclear.
Peptides are short chains of amino acids that occur naturally in the body and are vital for various biological processes. Notably, some peptide-based medications, such as GLP-1 drugs like Ozempic and Wegovy, have gained significant recognition. However, the seven peptides currently under review are part of a different category, marketed for a broader range of conditions, including ulcerative colitis and chronic pain, as well as for uses related to obesity and insomnia.
Among the compounds being examined are BPC-157, TB-500, and KPV. Their growing popularity has been propelled by social media influencers and the “looksmaxxing” trend. Health Secretary Robert F. Kennedy Jr. has publicly endorsed their use, claiming personal success and criticizing current restrictions that he argues drive consumers to an unregulated market.
Despite the increasing demand, scientists at the FDA have raised alarms about the lack of rigorous clinical trials underpinning many peptides. Preceding the advisory committee meeting, the FDA cited insufficient evidence on the safety and effectiveness of the seven peptides, highlighting concerns regarding their quality and consistency.
Discussion surrounding the review is further complicated by the connections of advisory committee members to the peptide industry. According to the Associated Press, seven of the committee’s 14 members have ties to businesses or clinics that offer peptide treatments. This includes physicians who operate clinics promoting peptide injections and Tennessee State Senator Bobby Harshbarger, whose family owns a pharmacy that sells compounded medications.
While the Department of Health and Human Services supports the committee’s integrity, it maintains that all members underwent standard ethics reviews and those failing to meet federal requirements were disqualified.
The recommendations from this advisory panel are not binding but are anticipated to significantly influence the FDA’s final decision regarding the regulation of these compounds. As the popularity of peptides continues to grow, the outcome of this review could have far-reaching implications for public health and safety.
